CJC-1295
Long-Acting GHRH Analogue Studied for Sustained Growth Hormone Pulses
Written by
BioPeptide Research Team
Medical review
Pending medical review
Overview
CJC-1295 is a modified analogue of growth-hormone-releasing hormone (GHRH), engineered to resist rapid enzymatic breakdown. It is studied for its potential to extend the duration of natural growth-hormone pulses released by the pituitary gland, and is often examined in research alongside ghrelin-receptor agonists such as Ipamorelin.
Proposed Mechanism
GHRH analogues like CJC-1295 are designed to bind GHRH receptors on the pituitary gland, prompting growth-hormone release in a manner intended to mirror — and in some formulations extend — the body's natural secretion rhythm. Some variants incorporate a Drug Affinity Complex (DAC) that researchers have studied for its effect on the peptide's circulating half-life.
Research Highlights
- Pharmacokinetic studies have compared the half-life and GH-release duration of DAC and non-DAC formulations
- Animal and in-vitro research has examined downstream effects on insulin-like growth factor 1 (IGF-1) levels following administration
- Published studies have investigated combined-administration protocols pairing GHRH analogues with ghrelin-receptor agonists to assess synergistic effects on GH-pulse amplitude
Research Dosing Reference
Rodent pituitary-axis studies
DAC-modified variants are studied on substantially different schedules than non-modified forms due to differing half-lives
Microgram-scale, subcutaneous — frequency depends on DAC vs. non-DAC formulation
Figures above are reported ranges from published animal/laboratory studies, summarized for academic reference — not recommendations for human or animal administration.
Reported Research Cycle Lengths
Reference guides commonly cite cycles of roughly 8 to 12 weeks for CJC-1295 — both the standard (no-DAC / Mod GRF) form, valued for short natural GH pulses, and the DAC-extended form, valued for sustained elevation — typically grouped with other GHRH-analogue literature.
Durations referenced here reflect ranges commonly cited across compound literature and reference guides — summarized for academic comparison only. They are not usage recommendations for humans or animals, and do not substitute for primary source review.
Reconstitution & Volume Calculator
A unit-conversion utility for laboratory use. It converts a vial strength and reconstitution volume into a draw volume — it performs arithmetic only and does not suggest, recommend, or imply an appropriate amount of CJC-1295 for any purpose.
Concentration
2500.0 mcg/mL
Draw volume
0.100 mL
Syringe reading
10.0 units
For laboratory research reference only — not medical advice, and not a dosing recommendation for human or animal use. "Syringe reading" assumes a standard U-100 (100 units per mL) insulin syringe.
Safety & Compliance Notes
- CJC-1295 has not received regulatory approval for human use and remains an investigational research compound
- Dosing figures reflect ranges discussed in published pharmacology literature, not usage instructions
- For in-vitro and animal research applications only
Research Citations
Verified PubMed citations for this compound are being compiled by our medical review team and will appear here once confirmed. In the meantime, search PubMed directly for independent peer-reviewed literature on this compound.
Research Grade · Lab Verified
Browse research-grade CJC-1295 and related compounds in our shop — shipped with a certificate of analysis, sold strictly for research purposes.
This page is provided for educational and research-reference purposes only and does not constitute medical advice, a treatment recommendation, or an endorsement of human use. Always consult primary peer-reviewed literature and a qualified professional before drawing conclusions about any compound. All products referenced are sold strictly for laboratory research — not for human consumption.